drugset / Trial / NCT05858710
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to explore a new therapeutic approach for advanced soft tissue sarcoma (STS) by investigating the safety, tolerability, and maximum tolerated dose (MTD)/highest tolerated dose (HTD) of DPPG2-TSL-DOX combined with regional hyperthermia (RHT) in patients who have been pre-treated with anthracycline, e.g. doxorubicin (DOX).
Timeline
- Start
- 2023-04-19
- Primary completion
- 2025-01-30
- Completion
- 2025-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Dexrazoxane | Small molecule | — | — |